Pablo Jara Martin· @pablojaramartin · X·· 1 day agoScore70
Body · original
Am I the only one at #ESMO26 who thinks FOURLIGHT-1 lacks an appropriate comparator? Why not use everolimus plus endocrine therapy (investigator’s choice) as the control arm, as in evERA? #ESMOAmbassadors @myESMO
11 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Pablo Jara Martin · x.com